Advanced Therapy Medicinal Products Market size was over USD 13.21 billion in 2024 and is projected to cross USD 67.8 billion by the end of 2037, witnessing more than 13.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of advanced therapy medicinal products is estimated at USD 14.63 billion. The growth of the market can be attributed to the increased prevalence of the genetic disorder. Drugs used in gene therapy are advanced therapy medicinal products that contain genes that have therapeutic, preventative, or diagnostic effects. Recombinant genes are inserted into the body to cure a number of illnesses, such as cancer, genetic problems, and chronic diseases. For instance, all over the world around 300 million people are living with a rare disease and it affects nearly 4% to 6% of the total world population.
In addition to these, factors that are believed to fuel the growth of the advanced therapy medicinal products market include higher adoption of gene therapy. Gene therapy is known to be one of the advanced therapy medicinal products. The therapy is used to treat the underlying genetic disorder by correcting the faulty gene in the body. In one study, 93 percent of respondents supported the use of gene therapy to treat Leber congenital amaurosis, an inherited form of blindness, while just 35 percent said it was certainly okay to use it to improve memory. Furthermore, advanced therapy medicinal products are used to replace or restore dopamine transmission in various parts of the nervous system. Therefore, increased cases of neurological ailment are anticipated the higher projection of the advanced therapy medicinal products market. According to the Pan American Health Organization’s 2019 statistics, around 7.5 million people are living with a neurological disorder and 533,172 deaths are due to the neurological condition.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2024-2037 |
|
CAGR |
13.3% |
|
Base Year Market Size (2024) |
USD 13.21 billion |
|
Forecast Year Market Size (2037) |
USD 67.8 billion |
|
Regional Scope |
|
Disease (Oncology, Genetic Disorder, CNS, Dermatology)
The global advanced therapy medicinal products market is segmented and analyzed for demand and supply by disease into oncology, genetic disorder, CNS, dermatology, and others. Out of all, the dermatology segment is to garner the highest revenue at the end of 2037, growing at a CAGR of 12.5% over the forecast period. The segment growth is expected on the back of rising cases of skin problems and cancer in the world. According to the World Health Organization, currently, 132,000 cases of melanoma and 2 to 3 million cases of non-melanoma skin cancer are reported annually worldwide. Skin cancer accounts for one in three cancer diagnoses, and one in five Americans will have it at some point in their lives.
Product (CAR-T Therapy, Gene Therapy, Cell Therapy, Tissue Engineered Product)
The global advanced therapy medicinal products market is also segmented and analyzed for demand and supply by product into CAR-T therapy, gene therapy, cell therapy, and tissue-engineered product. Amongst these four segments, the gene therapy segment is expected to grow at a CAGR of 13.8% over the forecast period. The segment growth is expected on the back of a higher number of people in need of gene therapy and growing clinical trials of gene therapy. By 2034, gene therapies could be used to treat more than 1 million Americans. Furthermore, in 2022, around 1221 cell and gene therapies are under active clinical trials, moreover, out of them nearly 324 clinical trials are in the phase of 1/1b.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Disease |
|
|
By End User |
|
North American Market Forecast
The North America advanced therapy medicinal products market, amongst the market in all the other regions, is projected to hold the largest industry share of 44% by 2037. The market growth in North America is attributed to higher cases of cancer and neurological disorder followed by investment by private companies for the development of advanced therapy medicinal products. In 2022, around 600,000 deaths are attributed to the cancer cases and nearly 2 million new cases of cancer were diagnosed in the United States. Furthermore, in 2019, Pfizer Inc. a leading U.S. based pharmaceutical company announced the investment of USD 500 million to expand the gene therapy manufacturing unit in Sanford, North Carolina.
Novartis AG in collaboration with Medicines for Malaria Venture announced the entry of novel ganaplacide/lumenfantrine-SDF into the phase 3 study. This novel is a combination to treat uncomplicated malaria in both adults and children.
Takeda Pharmaceutical Company Limited announced the collaboration and licensing agreement with Zedira and Dr.Falk Pharma for the development of first in class Celiac disease therapy. It is a serious autoimmune disease, in which intake of gluten damages the small intestine.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?